Healthcare M&A Poised for a Rebound in 2025

Following a subdued 2024, healthcare M&A and financing activity is gaining momentum in 2025. Lower interest rates, stronger credit markets, and a return of private equity capital are fueling deal flow, particularly in scalable, tech-driven sectors. Corporates and sponsors are re-engaging with strategic acquisitions, but face a regulatory environment that is more active and complex than ever.

We discuss the market in detail, including the following trends, in our recent article “Healthcare M&A and Financing in 2025,” which was published by LaingBuisson:

• Private equity is re-entering with focus on carve-outs, sponsor-to-sponsor deals, and consolidation in high-margin verticals.
• AI-driven healthtech, precision medicine, and aging care are leading the list of investor-favored subsectors.
• Venture capital is shifting toward later-stage companies with proven clinical and commercial traction.
• Antitrust scrutiny is intensifying across the US, UK, and EU, reshaping deal strategies and buyer profiles.

Click for a preview or return on July 1, 2025 for the full article.

This informational piece, which may be considered advertising under the ethical rules of certain jurisdictions, is provided on the understanding that it does not constitute the rendering of legal advice or other professional advice by Goodwin or its lawyers. Prior results do not guarantee similar outcomes.